- $487.53m
- $382.50m
- 55
- 28
- 87
- 57
Annual income statement for Eliem Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 7.45 | 20.9 | 35.7 | 45.1 | 40.3 |
Operating Profit | -7.45 | -20.9 | -35.7 | -45.1 | -40.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.55 | -20.7 | -47.5 | -45.2 | -35.1 |
Net Income After Taxes | -6.55 | -20.7 | -47.5 | -45.2 | -35.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.55 | -20.7 | -47.5 | -45.2 | -35.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.39 | -23 | -52 | -45.2 | -35.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.291 | -0.905 | -4.24 | -1.72 | -0.604 |
Dividends per Share |